Psyence BioMed (NASDAQ: PBM) is advancing its vertical integration strategy with a new $500,000 follow-on investment in PsyLabs, a specialist in manufacturing psychedelic pharmaceutical ingredients. Shares surged over 26% following the announcement, reflecting market enthusiasm for the company’s deepening footprint in the psychedelic therapeutics space.
This latest investment builds on a prior partnership established in 2024, which gave Psyence BioMed an 11.13% equity stake in PsyLabs along with exclusive rights to nature-derived, pharmaceutical-grade psilocybin for use in clinical trials targeting substance use disorders (SUD).
The new agreement also includes a global right of first refusal for the supply of ibogaine—an emerging psychedelic with early clinical promise in addiction treatment, particularly Alcohol Use Disorder (AUD). Under the terms, PsyLabs will provide Psyence BioMed the option to secure worldwide ibogaine sourcing rights as part of its future therapeutic development.
Ibogaine, a psychoactive compound extracted from the African Tabernanthe iboga plant, has gained attention for its potential to disrupt addictive behaviors through a unique mechanism of action. By locking in early access to high-quality ibogaine, Psyence BioMed positions itself to lead in a growing field of psychedelic-based alternatives to conventional addiction therapies.
CEO Dr. Neil Maresky said the partnership will help accelerate innovation in mental health, while PsyLabs CEO Tony Budden highlighted the strength of combining Psyence BioMed’s clinical expertise with PsyLabs’ global manufacturing infrastructure.
The investment aligns with Psyence BioMed’s broader goal of building a multi-asset psychedelics platform grounded in proprietary IP, secure supply chains, and advanced clinical development. The company remains focused on expanding access to regulated, nature-derived compounds as it pushes toward FDA-approved therapies.
The agreement is subject to standard closing terms and regulatory approvals, including the finalization of the ibogaine supply rights.
The post Psyence BioMed Deepens Psychedelic Supply Chain with $500K PsyLabs Investment and Exclusive Ibogaine Rights appeared first on PRISM MarketView.